Report Detail
Global Factor VIII Deficiency Treatment Market Size, Status and Forecast 2019-2025
- RnM3402724 |
- 16 July, 2019 |
- Global |
- 101 Pages |
- QYResearch |
- Other
Factor VIII is an essential blood-clotting protein, which is also known as an antihemophilic factor. In individuals, factor VIII is encoded by F8 gene. Defects in F8 gene lead to hemophilia A, a recessive X-linked coagulation disorder. Factor VIII is generated in liver sinusoidal cells and endothelial cells outside the liver across the body. This protein mixes in the bloodstream in an inactive form, and binds to another molecule called von Willebrand factor, until a damage to blood vessels occur. In response to injury, coagulation factor VIII gets activated and separates from von Willebrand factor.
The global hemophilia A drugs market segment accounted for the majority market share and will continue to dominate the factor 8 deficiency treatment market for the next few years. Some of the major factors responsible for the market segment's growth is the growing incidence of hemophilia A, the development of novel drugs with extended action, and the increased adoption of prophylactic treatment. Additionally, growing demand for novel recombinant extended half-life products, the emergence of monoclonal antibodies and gene therapy products, and launch of plasma-derived products for recombinant factor VIII at low costs, will also further drive the growth of the factor VIII deficiency treatment market.
In 2018, the global Factor VIII Deficiency Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Factor VIII Deficiency Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Factor VIII Deficiency Treatment development in United States, Europe and China.
The key players covered in this study
Pfizer
Shire
Bayer HealthCare
CSL
Grifols
Novo Nordisk
F. Hoffmann-La Roche
Kedrion
Octapharma
Biogen Idec
BioMarin Pharmaceutical
Sangamo Therapeutics
Spark Therapeutics
Swedish Orphan Biovitrum
Uniqure NV
Amarna Therapeutics
Dimension Therapeutics
Market segment by Type, the product can be split into
Hemophilia A Drugs
Hemophilia A Inhibitors Treatment
Von Willebrand Disease Treatment
Market segment by Application, split into
Hospitals
Clinics
Other
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Factor VIII Deficiency Treatment status, future forecast, growth opportunity, key market and key players.
To present the Factor VIII Deficiency Treatment development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Factor VIII Deficiency Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered
- 1.4 Market Analysis by Type
- 1.4.1 Global Factor VIII Deficiency Treatment Market Size Growth Rate by Type (2014-2025)
- 1.4.2 Hemophilia A Drugs
- 1.4.3 Hemophilia A Inhibitors Treatment
- 1.4.4 Von Willebrand Disease Treatment
- 1.5 Market by Application
- 1.5.1 Global Factor VIII Deficiency Treatment Market Share by Application (2014-2025)
- 1.5.2 Hospitals
- 1.5.3 Clinics
- 1.5.4 Other
- 1.6 Study Objectives
- 1.7 Years Considered
2 Global Growth Trends
- 2.1 Factor VIII Deficiency Treatment Market Size
- 2.2 Factor VIII Deficiency Treatment Growth Trends by Regions
- 2.2.1 Factor VIII Deficiency Treatment Market Size by Regions (2014-2025)
- 2.2.2 Factor VIII Deficiency Treatment Market Share by Regions (2014-2019)
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
- 2.3.3 Market Opportunities
3 Market Share by Key Players
- 3.1 Factor VIII Deficiency Treatment Market Size by Manufacturers
- 3.1.1 Global Factor VIII Deficiency Treatment Revenue by Manufacturers (2014-2019)
- 3.1.2 Global Factor VIII Deficiency Treatment Revenue Market Share by Manufacturers (2014-2019)
- 3.1.3 Global Factor VIII Deficiency Treatment Market Concentration Ratio (CR5 and HHI)
- 3.2 Factor VIII Deficiency Treatment Key Players Head office and Area Served
- 3.3 Key Players Factor VIII Deficiency Treatment Product/Solution/Service
- 3.4 Date of Enter into Factor VIII Deficiency Treatment Market
- 3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
- 4.1 Global Factor VIII Deficiency Treatment Market Size by Type (2014-2019)
- 4.2 Global Factor VIII Deficiency Treatment Market Size by Application (2014-2019)
5 United States
- 5.1 United States Factor VIII Deficiency Treatment Market Size (2014-2019)
- 5.2 Factor VIII Deficiency Treatment Key Players in United States
- 5.3 United States Factor VIII Deficiency Treatment Market Size by Type
- 5.4 United States Factor VIII Deficiency Treatment Market Size by Application
6 Europe
- 6.1 Europe Factor VIII Deficiency Treatment Market Size (2014-2019)
- 6.2 Factor VIII Deficiency Treatment Key Players in Europe
- 6.3 Europe Factor VIII Deficiency Treatment Market Size by Type
- 6.4 Europe Factor VIII Deficiency Treatment Market Size by Application
7 China
- 7.1 China Factor VIII Deficiency Treatment Market Size (2014-2019)
- 7.2 Factor VIII Deficiency Treatment Key Players in China
- 7.3 China Factor VIII Deficiency Treatment Market Size by Type
- 7.4 China Factor VIII Deficiency Treatment Market Size by Application
8 Japan
- 8.1 Japan Factor VIII Deficiency Treatment Market Size (2014-2019)
- 8.2 Factor VIII Deficiency Treatment Key Players in Japan
- 8.3 Japan Factor VIII Deficiency Treatment Market Size by Type
- 8.4 Japan Factor VIII Deficiency Treatment Market Size by Application
9 Southeast Asia
- 9.1 Southeast Asia Factor VIII Deficiency Treatment Market Size (2014-2019)
- 9.2 Factor VIII Deficiency Treatment Key Players in Southeast Asia
- 9.3 Southeast Asia Factor VIII Deficiency Treatment Market Size by Type
- 9.4 Southeast Asia Factor VIII Deficiency Treatment Market Size by Application
10 India
- 10.1 India Factor VIII Deficiency Treatment Market Size (2014-2019)
- 10.2 Factor VIII Deficiency Treatment Key Players in India
- 10.3 India Factor VIII Deficiency Treatment Market Size by Type
- 10.4 India Factor VIII Deficiency Treatment Market Size by Application
11 Central & South America
- 11.1 Central & South America Factor VIII Deficiency Treatment Market Size (2014-2019)
- 11.2 Factor VIII Deficiency Treatment Key Players in Central & South America
- 11.3 Central & South America Factor VIII Deficiency Treatment Market Size by Type
- 11.4 Central & South America Factor VIII Deficiency Treatment Market Size by Application
12 International Players Profiles
- 12.1 Pfizer
- 12.1.1 Pfizer Company Details
- 12.1.2 Company Description and Business Overview
- 12.1.3 Factor VIII Deficiency Treatment Introduction
- 12.1.4 Pfizer Revenue in Factor VIII Deficiency Treatment Business (2014-2019)
- 12.1.5 Pfizer Recent Development
- 12.2 Shire
- 12.2.1 Shire Company Details
- 12.2.2 Company Description and Business Overview
- 12.2.3 Factor VIII Deficiency Treatment Introduction
- 12.2.4 Shire Revenue in Factor VIII Deficiency Treatment Business (2014-2019)
- 12.2.5 Shire Recent Development
- 12.3 Bayer HealthCare
- 12.3.1 Bayer HealthCare Company Details
- 12.3.2 Company Description and Business Overview
- 12.3.3 Factor VIII Deficiency Treatment Introduction
- 12.3.4 Bayer HealthCare Revenue in Factor VIII Deficiency Treatment Business (2014-2019)
- 12.3.5 Bayer HealthCare Recent Development
- 12.4 CSL
- 12.4.1 CSL Company Details
- 12.4.2 Company Description and Business Overview
- 12.4.3 Factor VIII Deficiency Treatment Introduction
- 12.4.4 CSL Revenue in Factor VIII Deficiency Treatment Business (2014-2019)
- 12.4.5 CSL Recent Development
- 12.5 Grifols
- 12.5.1 Grifols Company Details
- 12.5.2 Company Description and Business Overview
- 12.5.3 Factor VIII Deficiency Treatment Introduction
- 12.5.4 Grifols Revenue in Factor VIII Deficiency Treatment Business (2014-2019)
- 12.5.5 Grifols Recent Development
- 12.6 Novo Nordisk
- 12.6.1 Novo Nordisk Company Details
- 12.6.2 Company Description and Business Overview
- 12.6.3 Factor VIII Deficiency Treatment Introduction
- 12.6.4 Novo Nordisk Revenue in Factor VIII Deficiency Treatment Business (2014-2019)
- 12.6.5 Novo Nordisk Recent Development
- 12.7 F. Hoffmann-La Roche
- 12.7.1 F. Hoffmann-La Roche Company Details
- 12.7.2 Company Description and Business Overview
- 12.7.3 Factor VIII Deficiency Treatment Introduction
- 12.7.4 F. Hoffmann-La Roche Revenue in Factor VIII Deficiency Treatment Business (2014-2019)
- 12.7.5 F. Hoffmann-La Roche Recent Development
- 12.8 Kedrion
- 12.8.1 Kedrion Company Details
- 12.8.2 Company Description and Business Overview
- 12.8.3 Factor VIII Deficiency Treatment Introduction
- 12.8.4 Kedrion Revenue in Factor VIII Deficiency Treatment Business (2014-2019)
- 12.8.5 Kedrion Recent Development
- 12.9 Octapharma
- 12.9.1 Octapharma Company Details
- 12.9.2 Company Description and Business Overview
- 12.9.3 Factor VIII Deficiency Treatment Introduction
- 12.9.4 Octapharma Revenue in Factor VIII Deficiency Treatment Business (2014-2019)
- 12.9.5 Octapharma Recent Development
- 12.10 Biogen Idec
- 12.10.1 Biogen Idec Company Details
- 12.10.2 Company Description and Business Overview
- 12.10.3 Factor VIII Deficiency Treatment Introduction
- 12.10.4 Biogen Idec Revenue in Factor VIII Deficiency Treatment Business (2014-2019)
- 12.10.5 Biogen Idec Recent Development
- 12.11 BioMarin Pharmaceutical
- 12.12 Sangamo Therapeutics
- 12.13 Spark Therapeutics
- 12.14 Swedish Orphan Biovitrum
- 12.15 Uniqure NV
- 12.16 Amarna Therapeutics
- 12.17 Dimension Therapeutics
13 Market Forecast 2019-2025
- 13.1 Market Size Forecast by Regions
- 13.2 United States
- 13.3 Europe
- 13.4 China
- 13.5 Japan
- 13.6 Southeast Asia
- 13.7 India
- 13.8 Central & South America
- 13.9 Market Size Forecast by Product (2019-2025)
- 13.10 Market Size Forecast by Application (2019-2025)
14 Analyst's Viewpoints/Conclusions
15 Appendix
- 15.1 Research Methodology
- 15.1.1 Methodology/Research Approach
- 15.1.1.1 Research Programs/Design
- 15.1.1.2 Market Size Estimation
- 12.1.1.3 Market Breakdown and Data Triangulation
- 15.1.2 Data Source
- 15.1.2.1 Secondary Sources
- 15.1.2.2 Primary Sources
- 15.1.1 Methodology/Research Approach
- 15.2 Disclaimer
Summary:
Get latest Market Research Reports on Factor VIII Deficiency Treatment . Industry analysis & Market Report on Factor VIII Deficiency Treatment is a syndicated market report, published as Global Factor VIII Deficiency Treatment Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Factor VIII Deficiency Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
